Medical Care
Global Gene Therapy for Neurodegenerative Diseases Market Research Report 2025
- May 12, 25
- ID: 236167
- Pages: 71
- Figures: 72
- Views: 4
The global market for Gene Therapy for Neurodegenerative Diseases was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Gene Therapy for Neurodegenerative Diseases is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Gene Therapy for Neurodegenerative Diseases is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Gene Therapy for Neurodegenerative Diseases in Hospitals and Clinics is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Gene Therapy for Neurodegenerative Diseases include Voyager Therapeutics, Uniqure N.V., Axovant Gene Therapies, Novartis Ag, Amicus Therapeutics, Regenxbio Inc., Sarepta Therapeutics, Gensight Biologics, Krystal Biotech, Avexis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy for Neurodegenerative Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy for Neurodegenerative Diseases.
The Gene Therapy for Neurodegenerative Diseases market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gene Therapy for Neurodegenerative Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Therapy for Neurodegenerative Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Voyager Therapeutics
Uniqure N.V.
Axovant Gene Therapies
Novartis Ag
Amicus Therapeutics
Regenxbio Inc.
Sarepta Therapeutics
Gensight Biologics
Krystal Biotech
Avexis
Segment by Type
Gene Replacement Therapy
Gene Silencing Therapy
Gene Editing Therapy
Enzyme Replacement Therapy
Segment by Application
Hospitals and Clinics
Research Institutions
Biotechnology Companies
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gene Therapy for Neurodegenerative Diseases company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
North American market for Gene Therapy for Neurodegenerative Diseases is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Gene Therapy for Neurodegenerative Diseases is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Gene Therapy for Neurodegenerative Diseases in Hospitals and Clinics is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Gene Therapy for Neurodegenerative Diseases include Voyager Therapeutics, Uniqure N.V., Axovant Gene Therapies, Novartis Ag, Amicus Therapeutics, Regenxbio Inc., Sarepta Therapeutics, Gensight Biologics, Krystal Biotech, Avexis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy for Neurodegenerative Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy for Neurodegenerative Diseases.
The Gene Therapy for Neurodegenerative Diseases market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Gene Therapy for Neurodegenerative Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Therapy for Neurodegenerative Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Voyager Therapeutics
Uniqure N.V.
Axovant Gene Therapies
Novartis Ag
Amicus Therapeutics
Regenxbio Inc.
Sarepta Therapeutics
Gensight Biologics
Krystal Biotech
Avexis
Segment by Type
Gene Replacement Therapy
Gene Silencing Therapy
Gene Editing Therapy
Enzyme Replacement Therapy
Segment by Application
Hospitals and Clinics
Research Institutions
Biotechnology Companies
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gene Therapy for Neurodegenerative Diseases company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Gene Replacement Therapy
1.2.3 Gene Silencing Therapy
1.2.4 Gene Editing Therapy
1.2.5 Enzyme Replacement Therapy
1.3 Market by Application
1.3.1 Global Gene Therapy for Neurodegenerative Diseases Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals and Clinics
1.3.3 Research Institutions
1.3.4 Biotechnology Companies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy for Neurodegenerative Diseases Market Perspective (2020-2031)
2.2 Global Gene Therapy for Neurodegenerative Diseases Growth Trends by Region
2.2.1 Global Gene Therapy for Neurodegenerative Diseases Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Gene Therapy for Neurodegenerative Diseases Historic Market Size by Region (2020-2025)
2.2.3 Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Region (2026-2031)
2.3 Gene Therapy for Neurodegenerative Diseases Market Dynamics
2.3.1 Gene Therapy for Neurodegenerative Diseases Industry Trends
2.3.2 Gene Therapy for Neurodegenerative Diseases Market Drivers
2.3.3 Gene Therapy for Neurodegenerative Diseases Market Challenges
2.3.4 Gene Therapy for Neurodegenerative Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy for Neurodegenerative Diseases Players by Revenue
3.1.1 Global Top Gene Therapy for Neurodegenerative Diseases Players by Revenue (2020-2025)
3.1.2 Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Players (2020-2025)
3.2 Global Gene Therapy for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Gene Therapy for Neurodegenerative Diseases Revenue
3.4 Global Gene Therapy for Neurodegenerative Diseases Market Concentration Ratio
3.4.1 Global Gene Therapy for Neurodegenerative Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy for Neurodegenerative Diseases Revenue in 2024
3.5 Global Key Players of Gene Therapy for Neurodegenerative Diseases Head office and Area Served
3.6 Global Key Players of Gene Therapy for Neurodegenerative Diseases, Product and Application
3.7 Global Key Players of Gene Therapy for Neurodegenerative Diseases, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Therapy for Neurodegenerative Diseases Breakdown Data by Type
4.1 Global Gene Therapy for Neurodegenerative Diseases Historic Market Size by Type (2020-2025)
4.2 Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Type (2026-2031)
5 Gene Therapy for Neurodegenerative Diseases Breakdown Data by Application
5.1 Global Gene Therapy for Neurodegenerative Diseases Historic Market Size by Application (2020-2025)
5.2 Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Gene Therapy for Neurodegenerative Diseases Market Size (2020-2031)
6.2 North America Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025)
6.4 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Therapy for Neurodegenerative Diseases Market Size (2020-2031)
7.2 Europe Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025)
7.4 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size (2020-2031)
8.2 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2020-2025)
8.4 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gene Therapy for Neurodegenerative Diseases Market Size (2020-2031)
9.2 Latin America Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025)
9.4 Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size (2020-2031)
10.2 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025)
10.4 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Voyager Therapeutics
11.1.1 Voyager Therapeutics Company Details
11.1.2 Voyager Therapeutics Business Overview
11.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.1.4 Voyager Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.1.5 Voyager Therapeutics Recent Development
11.2 Uniqure N.V.
11.2.1 Uniqure N.V. Company Details
11.2.2 Uniqure N.V. Business Overview
11.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Introduction
11.2.4 Uniqure N.V. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.2.5 Uniqure N.V. Recent Development
11.3 Axovant Gene Therapies
11.3.1 Axovant Gene Therapies Company Details
11.3.2 Axovant Gene Therapies Business Overview
11.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Introduction
11.3.4 Axovant Gene Therapies Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.3.5 Axovant Gene Therapies Recent Development
11.4 Novartis Ag
11.4.1 Novartis Ag Company Details
11.4.2 Novartis Ag Business Overview
11.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Introduction
11.4.4 Novartis Ag Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.4.5 Novartis Ag Recent Development
11.5 Amicus Therapeutics
11.5.1 Amicus Therapeutics Company Details
11.5.2 Amicus Therapeutics Business Overview
11.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.5.4 Amicus Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.5.5 Amicus Therapeutics Recent Development
11.6 Regenxbio Inc.
11.6.1 Regenxbio Inc. Company Details
11.6.2 Regenxbio Inc. Business Overview
11.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Introduction
11.6.4 Regenxbio Inc. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.6.5 Regenxbio Inc. Recent Development
11.7 Sarepta Therapeutics
11.7.1 Sarepta Therapeutics Company Details
11.7.2 Sarepta Therapeutics Business Overview
11.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.7.4 Sarepta Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.7.5 Sarepta Therapeutics Recent Development
11.8 Gensight Biologics
11.8.1 Gensight Biologics Company Details
11.8.2 Gensight Biologics Business Overview
11.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Introduction
11.8.4 Gensight Biologics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.8.5 Gensight Biologics Recent Development
11.9 Krystal Biotech
11.9.1 Krystal Biotech Company Details
11.9.2 Krystal Biotech Business Overview
11.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Introduction
11.9.4 Krystal Biotech Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.9.5 Krystal Biotech Recent Development
11.10 Avexis
11.10.1 Avexis Company Details
11.10.2 Avexis Business Overview
11.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Introduction
11.10.4 Avexis Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.10.5 Avexis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Gene Replacement Therapy
1.2.3 Gene Silencing Therapy
1.2.4 Gene Editing Therapy
1.2.5 Enzyme Replacement Therapy
1.3 Market by Application
1.3.1 Global Gene Therapy for Neurodegenerative Diseases Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals and Clinics
1.3.3 Research Institutions
1.3.4 Biotechnology Companies
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy for Neurodegenerative Diseases Market Perspective (2020-2031)
2.2 Global Gene Therapy for Neurodegenerative Diseases Growth Trends by Region
2.2.1 Global Gene Therapy for Neurodegenerative Diseases Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Gene Therapy for Neurodegenerative Diseases Historic Market Size by Region (2020-2025)
2.2.3 Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Region (2026-2031)
2.3 Gene Therapy for Neurodegenerative Diseases Market Dynamics
2.3.1 Gene Therapy for Neurodegenerative Diseases Industry Trends
2.3.2 Gene Therapy for Neurodegenerative Diseases Market Drivers
2.3.3 Gene Therapy for Neurodegenerative Diseases Market Challenges
2.3.4 Gene Therapy for Neurodegenerative Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy for Neurodegenerative Diseases Players by Revenue
3.1.1 Global Top Gene Therapy for Neurodegenerative Diseases Players by Revenue (2020-2025)
3.1.2 Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Players (2020-2025)
3.2 Global Gene Therapy for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Gene Therapy for Neurodegenerative Diseases Revenue
3.4 Global Gene Therapy for Neurodegenerative Diseases Market Concentration Ratio
3.4.1 Global Gene Therapy for Neurodegenerative Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy for Neurodegenerative Diseases Revenue in 2024
3.5 Global Key Players of Gene Therapy for Neurodegenerative Diseases Head office and Area Served
3.6 Global Key Players of Gene Therapy for Neurodegenerative Diseases, Product and Application
3.7 Global Key Players of Gene Therapy for Neurodegenerative Diseases, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Therapy for Neurodegenerative Diseases Breakdown Data by Type
4.1 Global Gene Therapy for Neurodegenerative Diseases Historic Market Size by Type (2020-2025)
4.2 Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Type (2026-2031)
5 Gene Therapy for Neurodegenerative Diseases Breakdown Data by Application
5.1 Global Gene Therapy for Neurodegenerative Diseases Historic Market Size by Application (2020-2025)
5.2 Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Gene Therapy for Neurodegenerative Diseases Market Size (2020-2031)
6.2 North America Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025)
6.4 North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Therapy for Neurodegenerative Diseases Market Size (2020-2031)
7.2 Europe Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025)
7.4 Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size (2020-2031)
8.2 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2020-2025)
8.4 Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gene Therapy for Neurodegenerative Diseases Market Size (2020-2031)
9.2 Latin America Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025)
9.4 Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size (2020-2031)
10.2 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025)
10.4 Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Voyager Therapeutics
11.1.1 Voyager Therapeutics Company Details
11.1.2 Voyager Therapeutics Business Overview
11.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.1.4 Voyager Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.1.5 Voyager Therapeutics Recent Development
11.2 Uniqure N.V.
11.2.1 Uniqure N.V. Company Details
11.2.2 Uniqure N.V. Business Overview
11.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Introduction
11.2.4 Uniqure N.V. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.2.5 Uniqure N.V. Recent Development
11.3 Axovant Gene Therapies
11.3.1 Axovant Gene Therapies Company Details
11.3.2 Axovant Gene Therapies Business Overview
11.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Introduction
11.3.4 Axovant Gene Therapies Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.3.5 Axovant Gene Therapies Recent Development
11.4 Novartis Ag
11.4.1 Novartis Ag Company Details
11.4.2 Novartis Ag Business Overview
11.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Introduction
11.4.4 Novartis Ag Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.4.5 Novartis Ag Recent Development
11.5 Amicus Therapeutics
11.5.1 Amicus Therapeutics Company Details
11.5.2 Amicus Therapeutics Business Overview
11.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.5.4 Amicus Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.5.5 Amicus Therapeutics Recent Development
11.6 Regenxbio Inc.
11.6.1 Regenxbio Inc. Company Details
11.6.2 Regenxbio Inc. Business Overview
11.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Introduction
11.6.4 Regenxbio Inc. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.6.5 Regenxbio Inc. Recent Development
11.7 Sarepta Therapeutics
11.7.1 Sarepta Therapeutics Company Details
11.7.2 Sarepta Therapeutics Business Overview
11.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
11.7.4 Sarepta Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.7.5 Sarepta Therapeutics Recent Development
11.8 Gensight Biologics
11.8.1 Gensight Biologics Company Details
11.8.2 Gensight Biologics Business Overview
11.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Introduction
11.8.4 Gensight Biologics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.8.5 Gensight Biologics Recent Development
11.9 Krystal Biotech
11.9.1 Krystal Biotech Company Details
11.9.2 Krystal Biotech Business Overview
11.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Introduction
11.9.4 Krystal Biotech Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.9.5 Krystal Biotech Recent Development
11.10 Avexis
11.10.1 Avexis Company Details
11.10.2 Avexis Business Overview
11.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Introduction
11.10.4 Avexis Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
11.10.5 Avexis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Gene Replacement Therapy
Table 3. Key Players of Gene Silencing Therapy
Table 4. Key Players of Gene Editing Therapy
Table 5. Key Players of Enzyme Replacement Therapy
Table 6. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Gene Therapy for Neurodegenerative Diseases Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Gene Therapy for Neurodegenerative Diseases Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Gene Therapy for Neurodegenerative Diseases Market Share by Region (2020-2025)
Table 10. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Gene Therapy for Neurodegenerative Diseases Market Share by Region (2026-2031)
Table 12. Gene Therapy for Neurodegenerative Diseases Market Trends
Table 13. Gene Therapy for Neurodegenerative Diseases Market Drivers
Table 14. Gene Therapy for Neurodegenerative Diseases Market Challenges
Table 15. Gene Therapy for Neurodegenerative Diseases Market Restraints
Table 16. Global Gene Therapy for Neurodegenerative Diseases Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Gene Therapy for Neurodegenerative Diseases Market Share by Players (2020-2025)
Table 18. Global Top Gene Therapy for Neurodegenerative Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Neurodegenerative Diseases as of 2024)
Table 19. Ranking of Global Top Gene Therapy for Neurodegenerative Diseases Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Gene Therapy for Neurodegenerative Diseases Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Gene Therapy for Neurodegenerative Diseases, Headquarters and Area Served
Table 22. Global Key Players of Gene Therapy for Neurodegenerative Diseases, Product and Application
Table 23. Global Key Players of Gene Therapy for Neurodegenerative Diseases, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Gene Therapy for Neurodegenerative Diseases Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2020-2025)
Table 27. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2026-2031)
Table 29. Global Gene Therapy for Neurodegenerative Diseases Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Application (2020-2025)
Table 31. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Application (2026-2031)
Table 33. North America Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031) & (US$ Million)
Table 48. Voyager Therapeutics Company Details
Table 49. Voyager Therapeutics Business Overview
Table 50. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 51. Voyager Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 52. Voyager Therapeutics Recent Development
Table 53. Uniqure N.V. Company Details
Table 54. Uniqure N.V. Business Overview
Table 55. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product
Table 56. Uniqure N.V. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 57. Uniqure N.V. Recent Development
Table 58. Axovant Gene Therapies Company Details
Table 59. Axovant Gene Therapies Business Overview
Table 60. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product
Table 61. Axovant Gene Therapies Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 62. Axovant Gene Therapies Recent Development
Table 63. Novartis Ag Company Details
Table 64. Novartis Ag Business Overview
Table 65. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product
Table 66. Novartis Ag Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 67. Novartis Ag Recent Development
Table 68. Amicus Therapeutics Company Details
Table 69. Amicus Therapeutics Business Overview
Table 70. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 71. Amicus Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 72. Amicus Therapeutics Recent Development
Table 73. Regenxbio Inc. Company Details
Table 74. Regenxbio Inc. Business Overview
Table 75. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product
Table 76. Regenxbio Inc. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 77. Regenxbio Inc. Recent Development
Table 78. Sarepta Therapeutics Company Details
Table 79. Sarepta Therapeutics Business Overview
Table 80. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 81. Sarepta Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 82. Sarepta Therapeutics Recent Development
Table 83. Gensight Biologics Company Details
Table 84. Gensight Biologics Business Overview
Table 85. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product
Table 86. Gensight Biologics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 87. Gensight Biologics Recent Development
Table 88. Krystal Biotech Company Details
Table 89. Krystal Biotech Business Overview
Table 90. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product
Table 91. Krystal Biotech Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 92. Krystal Biotech Recent Development
Table 93. Avexis Company Details
Table 94. Avexis Business Overview
Table 95. Avexis Gene Therapy for Neurodegenerative Diseases Product
Table 96. Avexis Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 97. Avexis Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
Table 101. Authors List of This Report
List of Figures
Figure 1. Gene Therapy for Neurodegenerative Diseases Picture
Figure 2. Global Gene Therapy for Neurodegenerative Diseases Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Gene Therapy for Neurodegenerative Diseases Market Share by Type: 2024 VS 2031
Figure 4. Gene Replacement Therapy Features
Figure 5. Gene Silencing Therapy Features
Figure 6. Gene Editing Therapy Features
Figure 7. Enzyme Replacement Therapy Features
Figure 8. Global Gene Therapy for Neurodegenerative Diseases Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Gene Therapy for Neurodegenerative Diseases Market Share by Application: 2024 VS 2031
Figure 10. Hospitals and Clinics Case Studies
Figure 11. Research Institutions Case Studies
Figure 12. Biotechnology Companies Case Studies
Figure 13. Others Case Studies
Figure 14. Gene Therapy for Neurodegenerative Diseases Report Years Considered
Figure 15. Global Gene Therapy for Neurodegenerative Diseases Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Gene Therapy for Neurodegenerative Diseases Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Gene Therapy for Neurodegenerative Diseases Market Share by Region: 2024 VS 2031
Figure 18. Global Gene Therapy for Neurodegenerative Diseases Market Share by Players in 2024
Figure 19. Global Top Gene Therapy for Neurodegenerative Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Neurodegenerative Diseases as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Gene Therapy for Neurodegenerative Diseases Revenue in 2024
Figure 21. North America Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Gene Therapy for Neurodegenerative Diseases Market Share by Country (2020-2031)
Figure 23. United States Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Gene Therapy for Neurodegenerative Diseases Market Share by Country (2020-2031)
Figure 27. Germany Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Share by Region (2020-2031)
Figure 35. China Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Gene Therapy for Neurodegenerative Diseases Market Share by Country (2020-2031)
Figure 43. Mexico Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Share by Country (2020-2031)
Figure 47. Turkey Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Voyager Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 51. Uniqure N.V. Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 52. Axovant Gene Therapies Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 53. Novartis Ag Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 54. Amicus Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 55. Regenxbio Inc. Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 56. Sarepta Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 57. Gensight Biologics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 58. Krystal Biotech Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 59. Avexis Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Gene Replacement Therapy
Table 3. Key Players of Gene Silencing Therapy
Table 4. Key Players of Gene Editing Therapy
Table 5. Key Players of Enzyme Replacement Therapy
Table 6. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Gene Therapy for Neurodegenerative Diseases Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Gene Therapy for Neurodegenerative Diseases Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Gene Therapy for Neurodegenerative Diseases Market Share by Region (2020-2025)
Table 10. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Gene Therapy for Neurodegenerative Diseases Market Share by Region (2026-2031)
Table 12. Gene Therapy for Neurodegenerative Diseases Market Trends
Table 13. Gene Therapy for Neurodegenerative Diseases Market Drivers
Table 14. Gene Therapy for Neurodegenerative Diseases Market Challenges
Table 15. Gene Therapy for Neurodegenerative Diseases Market Restraints
Table 16. Global Gene Therapy for Neurodegenerative Diseases Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Gene Therapy for Neurodegenerative Diseases Market Share by Players (2020-2025)
Table 18. Global Top Gene Therapy for Neurodegenerative Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Neurodegenerative Diseases as of 2024)
Table 19. Ranking of Global Top Gene Therapy for Neurodegenerative Diseases Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Gene Therapy for Neurodegenerative Diseases Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Gene Therapy for Neurodegenerative Diseases, Headquarters and Area Served
Table 22. Global Key Players of Gene Therapy for Neurodegenerative Diseases, Product and Application
Table 23. Global Key Players of Gene Therapy for Neurodegenerative Diseases, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Gene Therapy for Neurodegenerative Diseases Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2020-2025)
Table 27. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Type (2026-2031)
Table 29. Global Gene Therapy for Neurodegenerative Diseases Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Application (2020-2025)
Table 31. Global Gene Therapy for Neurodegenerative Diseases Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Gene Therapy for Neurodegenerative Diseases Revenue Market Share by Application (2026-2031)
Table 33. North America Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size by Country (2026-2031) & (US$ Million)
Table 48. Voyager Therapeutics Company Details
Table 49. Voyager Therapeutics Business Overview
Table 50. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 51. Voyager Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 52. Voyager Therapeutics Recent Development
Table 53. Uniqure N.V. Company Details
Table 54. Uniqure N.V. Business Overview
Table 55. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product
Table 56. Uniqure N.V. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 57. Uniqure N.V. Recent Development
Table 58. Axovant Gene Therapies Company Details
Table 59. Axovant Gene Therapies Business Overview
Table 60. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product
Table 61. Axovant Gene Therapies Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 62. Axovant Gene Therapies Recent Development
Table 63. Novartis Ag Company Details
Table 64. Novartis Ag Business Overview
Table 65. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product
Table 66. Novartis Ag Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 67. Novartis Ag Recent Development
Table 68. Amicus Therapeutics Company Details
Table 69. Amicus Therapeutics Business Overview
Table 70. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 71. Amicus Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 72. Amicus Therapeutics Recent Development
Table 73. Regenxbio Inc. Company Details
Table 74. Regenxbio Inc. Business Overview
Table 75. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product
Table 76. Regenxbio Inc. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 77. Regenxbio Inc. Recent Development
Table 78. Sarepta Therapeutics Company Details
Table 79. Sarepta Therapeutics Business Overview
Table 80. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 81. Sarepta Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 82. Sarepta Therapeutics Recent Development
Table 83. Gensight Biologics Company Details
Table 84. Gensight Biologics Business Overview
Table 85. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product
Table 86. Gensight Biologics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 87. Gensight Biologics Recent Development
Table 88. Krystal Biotech Company Details
Table 89. Krystal Biotech Business Overview
Table 90. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product
Table 91. Krystal Biotech Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 92. Krystal Biotech Recent Development
Table 93. Avexis Company Details
Table 94. Avexis Business Overview
Table 95. Avexis Gene Therapy for Neurodegenerative Diseases Product
Table 96. Avexis Revenue in Gene Therapy for Neurodegenerative Diseases Business (2020-2025) & (US$ Million)
Table 97. Avexis Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
Table 101. Authors List of This Report
List of Figures
Figure 1. Gene Therapy for Neurodegenerative Diseases Picture
Figure 2. Global Gene Therapy for Neurodegenerative Diseases Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Gene Therapy for Neurodegenerative Diseases Market Share by Type: 2024 VS 2031
Figure 4. Gene Replacement Therapy Features
Figure 5. Gene Silencing Therapy Features
Figure 6. Gene Editing Therapy Features
Figure 7. Enzyme Replacement Therapy Features
Figure 8. Global Gene Therapy for Neurodegenerative Diseases Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Gene Therapy for Neurodegenerative Diseases Market Share by Application: 2024 VS 2031
Figure 10. Hospitals and Clinics Case Studies
Figure 11. Research Institutions Case Studies
Figure 12. Biotechnology Companies Case Studies
Figure 13. Others Case Studies
Figure 14. Gene Therapy for Neurodegenerative Diseases Report Years Considered
Figure 15. Global Gene Therapy for Neurodegenerative Diseases Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Gene Therapy for Neurodegenerative Diseases Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Gene Therapy for Neurodegenerative Diseases Market Share by Region: 2024 VS 2031
Figure 18. Global Gene Therapy for Neurodegenerative Diseases Market Share by Players in 2024
Figure 19. Global Top Gene Therapy for Neurodegenerative Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Neurodegenerative Diseases as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Gene Therapy for Neurodegenerative Diseases Revenue in 2024
Figure 21. North America Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Gene Therapy for Neurodegenerative Diseases Market Share by Country (2020-2031)
Figure 23. United States Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Gene Therapy for Neurodegenerative Diseases Market Share by Country (2020-2031)
Figure 27. Germany Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Gene Therapy for Neurodegenerative Diseases Market Share by Region (2020-2031)
Figure 35. China Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Gene Therapy for Neurodegenerative Diseases Market Share by Country (2020-2031)
Figure 43. Mexico Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Gene Therapy for Neurodegenerative Diseases Market Share by Country (2020-2031)
Figure 47. Turkey Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Voyager Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 51. Uniqure N.V. Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 52. Axovant Gene Therapies Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 53. Novartis Ag Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 54. Amicus Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 55. Regenxbio Inc. Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 56. Sarepta Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 57. Gensight Biologics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 58. Krystal Biotech Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 59. Avexis Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2020-2025)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Allergen Detection Market Research Report 2025
Jun 28, 25
Global Electronic Health Tracking System Market Research Report 2025
Jun 28, 25
Global Speciality Optical Fibers Market Research Report 2025
Jun 28, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232